The common agerelated neurodegenera tive diseases, Alzheimer disease (AD) and Parkinson disease (PD), are already major public health problems for older indivi duals and are poised to amplify tragically with our increasingly aging population. PD is one of a group of neurodegenerative diseases called 'synucleinopathies' , all of which share the pathological feature of αsynuclein containing inclusions, whether in neurons or glia. Other diseases in the synucleino pathy set include dementia with Lewy bodies (DLB, a complex mix of at least two entities that commonly is comorbid with AD), and multiple system atrophy (MSA, which can be difficult to distinguish clinically from PD, especially in early stages of disease). These facts compel a thera peutic imperative that is pursued currently by many laborato ries worldwide in search of etiologies, key pathogenic steps, and effective inter ventions that at least treat, and hopefully even cure, these diseases. A key component of the response to this therapeutic imperative is the develop ment of biomarkers, a type of laboratory data that can be used in disease evaluations, and the role of which is to signal the presence and/or burden of disease. As with decreased cerebrospinal fluid (CSF) levels of amyloidβ (Αβ) 42 in AD, concentra tions of αsynuclein have been observed to be decreased in patients with PD compared with controls by several groups of investiga tors; however, not all groups have been able to reproduce this finding, leading to dis cussions about the specific protocols used, the degree of CSF contamination by blood, and sample storage. In a study published by The Lancet Neurology, Mollenhauer and colleagues 1 contribute to this litera ture by confirming that αsynuclein levels are decreased in the CSF of patients with PD, and in those with other synucleino pathies, and could be a useful diagnostic biomark er for these diseases.
In their excellent crosssectional study, Mollenhauer and colleagues 1 assessed levels of αsynuclein in control individuals without neurological disease, patients with AD, patients with PD or other synucleino pathies, and patients with a mix of other neuro logical diseases. Total αsynuclein levels in the CSF and serum, as well as total CSF tau levels, were measured in three cohorts of patients, a training cohort (n = 273), a cohort with autopsyconfirmed neurologi cal disease (n = 41) and a validation cohort (n = 407). The researchers confirmed that αsynuclein concentration (as determined by enzymelinked immunosorbent assay) was substantially reduced in patients with any one of the three synucleinopathies (PD, DLB and MSA).
Mollenhauer and colleagues 1 also investi gated CSF tau and Aβ 42 levels in their cohorts and observed the expected changes of increased tau and decreased Aβ 42 concen trations in patients with AD, but no marked changes in either protein was observed in patients with PD. Many groups have investi gated these AD biomarkers in patients with PD and the literature is conflicting. One impor tant variable may be the level of cog nitive impairment in patients with PD, which has received increasing attention and was probably underappreciated in early studies. Some work from the past year sug gests that patients with PD plus dementia have reduced CSF levels of Aβ 42 compared with controls, but not increased CSF levels of tau. 2 One speculation from these data is that the dopa minergic neurodegeneration that occurs in PD may clinically unmask AD at an early stage in some patients, when Aβ 42 is being deposited in parenchyma (and decreasing in CSF), but before the occurrence of largescale neuron death and increasing concentrations of tau in CSF.
Biomarkers are quantitative measures of dynamic processes that reflect ongoing dis ease. This notion stands in sharp distinc tion to risk assessment, (commonly carried out in the laboratory setting by genetic testing), because risk factors are, at least for now, immutable and are used to esti mate the likelihood of future disease. The roles of biomarkers in neurodegenerative disease are potentially transformative and include: detecting disease in its latency and thereby providing an opportunity for early intervention; aiding in diagno sis and thereby guiding the assemblage of moreuniform clinical trial cohorts with reduced variance and smaller required size; provid ing robust quantitation of dis ease progression and thereby reducing the time to primary outcome in clinical trials; and, ultimately, assisting healthcare providers in the medical management of patients with these diseases. My colleagues and I have proposed a simple and practi cal fivelevel ranking for the develop ment of bio markers for use in the clinic (Box 1). 3 The AD Neuroimaging Initiative has now taken the arduous step of moving to level IV biomarker development criteria for reduced CSF Aβ 42 levels and increased CSF tau concentrations in individuals with AD at dementia and prodromal stages, and probably in latency as well. 4 Further more, elegant imaging studies, a few but tressed by subsequent post mortem examina tion, indicate that decreased CSF levels of Aβ 42 in individuals with AD is associ ated with increased accumulation of this peptide in brain. 5 The basis for increased CSF tau concentration in AD is more specu lative, but occurs in several degenerative and des tructive diseases of the brain and may be a co nsequence of neuron al injury.
''
The roles of biomarkers in neurodegenerative disease are potentially transformative…
Given the clinical potential of bio markers and the successes achieved so far in AD, many investigators are pursuing bio markers for other neurodegenerative diseases. PD is now a major area of focus for biomarker research, as evidenced by the establish ment of the Parkinson's Progression Markers Initi ative (PPMI), sponsored by the Michael J. Fox Foundation, and the Parkinson's Dis ease Biomarkers Identification Network (PD BIN) by the National Institute of Neuro logical Disorders and Stroke, USA. The finding by Mollenhauer and co workers 1 is an important step forward and, combined with the results from another 2011 study 6 that reached similar conclusions, achieves solid level III development cri teria for decreased CSF levels of αsynuclein as a biomarker for synucleinopathies. The next step to achieve level IV development for this synucleinopathy biomarker awaits the outcome of large multicenter studies, such as PPMI and PDBIN.
Interestingly, several studies, including the one by Mollenhauer et al.,
1 have yet to identify abnormal CSF αsynuclein con centrations in a subset of asympto matic control patients, as has been observed with CSF Aβ 42 and tau, 3 perhaps because of reduced prevalence of latent synucleino pathies. More over, the results from these studies indicate that the performance charac teristics of CSF αsynuclein con centrations as a clinical laboratory test are insufficient as a single measure, and that the need for improved laboratory testing for individuals with PD or related diseases is clear. Some areas for future investigation of αsynuclein as a PD biomarker include the relevance of specific isoforms, applica tion in different atrisk groups of PD, and use of other biofluid compart ments (such as plasma or saliva) for the measurement of this protein. 7, 8 The search continues for risk factors, molecular neuro imaging agents, and other biomarkers to combine with mea sures of CSF αsynuclein concentrations, to improve performance of clinical laboratory testing for PD. 
